Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Surufatinib for the Treatment of Advanced Pancreatic Neuroendocrine Tumors

Surufatinib for the Treatment of Advanced Pancreatic Neuroendocrine Tumors

The Lancet Oncology reported that SANET-p, a phase-III clinical trial, found that, in patients with advanced pancreatic neuroendocrine tumors, compared with placebo, surufatinib significantly improved progression-free survival. Surufatinib targets VEGFR-1, VEGFR-2, VEGFR-3, FGFR1 and CSF-1R and belongs to the anti-angiogenesis class as a new small-molecule inhibitor drug.

Study Details

This double-blind, multicenter study in China included 172 patients who had previously received 2 lines of systemic treatment for advanced, well-differentiated pancreatic neuroendocrine tumors. Between February 2016 and November 2019, patients were randomly assigned in a 2:1 ratio to receive oral surufatinib 300 mg once daily (113 patients) or placebo (59 patients) in consecutive 4-week cycles until disease progression, intolerable side effects or poor treatment adherence. Patients in the placebo group with disease progression were allowed to cross over to surufatinib.

The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population.

Progression-Free Survival Results

  • A prespecified interim analysis was performed at a median follow-up of 19.3 months in the surufatinib group and 11.1 months in the placebo group.
  • Median progression-free survival was 10.9 months in the surufatinib group (95% confidence interval [CI] = 7.5-13.8 months) and 3.7 months in the placebo group (95% CI = 2.8-5.6 months) (hazard ratio [HR] = 0.49, 95% CI = 0.32–0.76; P = 0.0011).
  • The trial met the early stopping criteria at the interim analysis and was ended on the recommendation of the independent data monitoring committee because of the large difference between the surufatinib and placebo arms.
  • On assessment by the blinded independent review committee, median progression-free survival was 13.9 months in the surufatinib group (95% CI = 11.0-24.9 months) and 4.6 months in the placebo group (95% CI = 3.6-7.4 months) (HR = 0.34, 95% CI = 0.21–0.55, P <0.0001).
  • A total of 31 of the 59 placebo-group patients (53%) crossed over to receive surufatinib.
  • Overall survival data were immature at the interim analysis; by the time of the analysis, 18% of patients in the surufatinib group and 15% in the placebo group had died.

Side Effects

  • The most common severe (grade ≥ 3) treatment-related side effects in the surufatinib group were hypertension (38% in the surufatinib arm versus 7% in the placebo group), proteinuria (10% versus 2%) and hypertriglyceridemia (7% versus 0%).
  • Serious treatment-related side effects were reported in 22% versus 7% of patients. The most frequently reported serious side effects in the surufatinib group were proteinuria in 4%, and ascites (fluid in the abdomen), diarrhea, gastrointestinal bleeding, vomiting and liver injury in 2%.
  • Adverse events led to death in two patients in the surufatinib group, from gastrointestinal bleeding (considered possibly treatment-related) and cerebral hemorrhage.

Conclusion

Surufatinib significantly improves progression-free survival and has an acceptable safety profile in patients with progressive, advanced pancreatic neuroendocrine tumors, and may be a potential treatment option for this group.

*

Further Reading: What Is a Neuroendocrine Tumor?

The neuroendocrine system consists of hormone-producing (endocrine) cells and nerve cells. Neuroendocrine cells are mainly found in organs such as the digestive system (stomach and intestines) and lungs. Neuroendocrine tumors can occur throughout the body but frequently arise in neuroendocrine cells in the gastrointestinal system, lungs and pancreas. They are rare cancers as a group.

what are neuroendocrine tumors

Most neuroendocrine tumors show no symptoms in their early stages and take years to grow. Some types, however, are aggressive and grow rapidly. This makes timely detection and control of the tumor difficult.

Standard treatment algorithm for locally advanced or metastatic pancreatic neuroendocrine tumors (NCCN guideline, 2018)

Standard treatment algorithm for locally advanced or metastatic pancreatic neuroendocrine tumors

RELATED TOPICS:

*

The video below can help explain pancreatic cancer types and treatments:

Sources

Prof Jianming Xu, Prof Lin Shen, Prof Chunmei Bai, Wei Wang, Prof Jie Li, Prof Xianjun Yu, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. THE LANCET Oncology, 20 Sep 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Surufatinib for the Treatment of Advanced Pancreatic Neuroendocrine Tumors

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy